Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-04-09 Regulatory Filings
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
113年3月營業收入
Regulatory Filings Classification · 85% confidence The document is a summarized revenue report for a company named 寶齡富錦 for the period of March 2024 (民國113年03月). It contains monthly and cumulative net operating revenue figures with percentage changes compared to the previous year. The text includes notes explaining accounting standards and reporting practices related to IFRS adoption. The document is short (768 characters) and primarily presents financial summary data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release with highlights. It is more of a regulatory or public disclosure of revenue figures, typical of a regulatory filing or a brief financial summary. Given the length and content, it is not a full financial report but a regulatory announcement of financial data. Therefore, the best fit is Regulatory Filings (RNS).
2024-04-09 Chinese
本公司受邀參加證交所主辦之113年生技醫療主題式業績發表會
Investor Presentation Classification · 85% confidence The document is a brief announcement about the company being invited to participate in a themed performance presentation event organized by the Taiwan Stock Exchange. It includes details about the date, time, and location of the investor presentation but does not contain any financial statements or detailed financial data. The document is short (656 characters) and serves as a notice of an upcoming investor presentation rather than the presentation itself. According to the rules, announcements about presentations or events without substantive financial content should be classified as Investor Presentation (IP) if they contain the presentation or Annual General Meeting materials (AGM-R) if related to AGM, but this is a notice of participation in an event, not the presentation content. Since it is an announcement of an event, the best fit is Investor Presentation (IP) as it relates to a presentation for investors focusing on financials and strategy, even though the actual presentation is not included here. Confidence is high due to clear event details and the nature of the announcement.
2024-04-03 Chinese
113年03月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings and changes in shareholdings by insiders, including directors, managers, and their related parties. It includes data on shares held at appointment, changes during the month, and current holdings, with specific mention of insiders and their share transactions. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider share transactions and holdings disclosures. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2024-04-02 Chinese
113年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders, including directors, supervisors, and senior management of the company 寶齡富錦生技股份有限公司. It lists current holdings, pledged shares, and related party holdings. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. This type of document corresponds to insider share transactions or holdings disclosures. Given the nature of the data, it fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives. The document length is 3187 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the classification is DIRS with high confidence.
2024-04-02 Chinese
112年度財務比率
Fund Information / Factsheet Classification · 95% confidence The document contains a financial data table summarizing key financial ratios and metrics for the company 寶齡富錦 over the last three fiscal years (110年度, 111年度, 112年度). The content is a concise financial summary without detailed narrative, management discussion, or full financial statements. The document length is only 1003 characters, which is quite short and resembles a brief financial factsheet rather than a full report. There is no indication that this is an announcement or notice about a report publication, nor is it a transcript, legal, or governance document. Given the concise financial data presentation and the short length, the document best fits the category of a Fund Information / Factsheet (FS), which is defined as a brief summary of key company facts and financials.
2024-03-14 Chinese
112年第4季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment holdings and related financial figures for a company named 寶齡富錦 (Bowlin Biotech). It includes details such as ownership percentages, original investment amounts, investment balances, and recognized investment gains or losses for the current period and prior year-end. The document is relatively short (1247 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report. There is no indication that this is an annual or interim report, audit report, or earnings release. It also does not contain management commentary, call transcripts, or governance information. The content fits best as a regulatory filing providing investment information disclosures, which is typical for filings on public information observation platforms. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.